Journal: bioRxiv
Article Title: Discovery of five HIV nucleoside analog reverse-transcriptase inhibitors (NRTIs) as potent inhibitors against the RNA-dependent RNA polymerase (RdRp) of SARS-CoV and 2019-nCoV
doi: 10.1101/2020.11.01.363788
Figure Lengend Snippet: (A) The activity of 2019-nCoV nsp12 was determined at different time-points which showed similar activities to SARS-CoV. 50% Glycerol incubated for 120 min was used as control. (B) Clofarabine, stavudine, gemcitabine, tenofovir, ganciclovir and remdesivir from SARS-CoV screening were selected and their inhibition on 2019-nCoV nsp12 was evaluated at 4 mM which showed inhibition as well. The assay condition was same as SARS-CoV. The analogs were evaluated in their corresponding triphosphate forms. ATP at 4 mM was used as normalization control. Same concentration of primer was loaded as negative control. (C) showed the percent of inhibition as compared to ATP of which the activity was defined as 100% and inhibition as zero.
Article Snippet: 6-Mercaptopurine-TP (NU-1110S), 6-chloropurine-TP (NU-1109S), clofarabine-TP (NU-874), 6-methylthio-GTP (NU-1130S), 6-thio-GTP (NU-1106S), stavudine-TP (NU-1604S), 8-oxo-GTP (NU-1116S), gemcitabine-TP (NU-1607S), acyclovir-TP (NU-877), ganciclovir-TP (NU-275S), lamivudine-TP (NU-1606L) and zidovudine-TP (NU-989S) were purchased from Jena Bioscience.
Techniques: Activity Assay, Incubation, Inhibition, Concentration Assay, Negative Control